Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| ICS-M5259 | Mouse | Mouse ICOS / CD278 (C137S, C138S) Protein, Fc Tag |  |
|
|
| ICS-M52H8 | Mouse | Mouse ICOS / CD278 (C137S, C138S) Protein, His Tag |  |
|
|
| ICS-H5258 | Human | Human ICOS / CD278 Protein, Fc Tag |  |
|
|
| ICS-H82E5 | Human | Biotinylated Human ICOS / CD278 (C136S, C137S) Protein, His,Avitag™ (recommended for biopanning) |  |
|
|
| ICS-H52H6 | Human | Human ICOS / CD278 (C136S, C137S) Protein, His Tag (MALS verified) |  |
|
|
Immobilized Human B7-H2, Fc Tag (Cat. No. B72-H5254) at 5 μg/mL (100 μL/well) can bind Mouse ICOS (C137S, C138S), His Tag (Cat. No. ICS-M52H8) with a linear range of 39-625 ng/mL (QC tested).
The purity of Human ICOS (C136S, C137S), His Tag (Cat. No. ICS-H52H6) was more than 85% and the molecular weight of this protein is around 22-34 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| KY-1044 | KY-1044 | Phase 2 Clinical | Kymab | Liver Neoplasms; Head and Neck Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular | Details |
| Anti-ICOS (Bristol Myers Squibb) | BMS-986226 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| ALPN-101 | ALPN-101 | Phase 2 Clinical | Alpine Immune Sciences | Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation | Details |
| XmAb-23104 (Xencor) | Phase 1 Clinical | Xencor | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Sarcoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details | |
| Vopratelimab | JTX-2011 | Phase 2 Clinical | Jounce Therapeutics | Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
| Feladilimab | GSK-3359609; GSK-609 | Phase 3 Clinical | Glaxosmithkline Plc | Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Multiple Myeloma | Details |
This web search service is supported by Google Inc.
A-Z